SciSparc Ltd. Stock

Equities

SPRC

IL0010951403

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
1.32 USD +4.76% Intraday chart for SciSparc Ltd. +7.32% -72.95%
Sales 2022 1.35 Sales 2023 2.88 Capitalization 2.56M
Net income 2022 -2M Net income 2023 -5M EV / Sales 2022 1,145,812 x
Net cash position 2022 3.55M Net cash position 2023 5M EV / Sales 2023 -848,893 x
P/E ratio 2022
-1.33 x
P/E ratio 2023
-0.34 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 99.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.76%
1 week+7.32%
Current month-25.42%
1 month-29.03%
3 months-71.30%
6 months-65.45%
Current year-72.95%
More quotes
1 week
1.15
Extreme 1.15
1.33
1 month
1.15
Extreme 1.15
2.10
Current year
1.15
Extreme 1.15
6.78
1 year
1.15
Extreme 1.15
23.66
3 years
0.00
Extreme 0.0026
221.00
5 years
0.00
Extreme 0.0026
221.00
10 years
0.00
Extreme 0.0026
221.00
More quotes
Date Price Change Volume
24-04-26 1.32 +4.76% 190,643
24-04-25 1.26 +4.13% 132,279
24-04-24 1.21 -1.63% 77,242
24-04-23 1.23 +0.82% 112,175
24-04-22 1.22 -0.81% 74,362

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
More about the company

Annual profits - Rate of surprise